title: Comparison of neointimal coverage between everolimus-eluting stents and sirolimus-eluting stents: an optical coherence tomography substudy of the RESET (Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial).
abstract: OBJECTIVE
  The aim of the present study was to compare vascular healing response between the first-generation sirolimus-eluting stent (SES) and the second-generation everolimus-eluting stent (EES) by using optical coherence tomography (OCT).
  
  
  RESULTS
  The RESET was a prospective, multicentre, randomised, open-label trial comparing EES and SES. Of the 3,197 patients enrolled in the RESET, nine-month follow-up OCT after stent implantation was performed in 100 patients (48 EES-treated lesions in 44 patients and 62 SES-treated lesions in 56 patients), thus constituting the OCT substudy population. The percentage of uncovered struts per lesion (8±15% vs. 14±19%, p=0.031) and cross-sections with >30% uncovered struts per lesion (6±14% vs. 18±29%, p=0.009) was significantly lower in EES compared with SES. The frequency of DES-treated lesions with incomplete stent apposition (8 [17%] vs. 29 [47%], p<0.001) was significantly lower in EES compared with SES. Intra-stent thrombus was comparably observed between EES and SES (1 [2%] vs. 5 [8%], p=0.229).
  
  
  CONCLUSIONS
  Compared with SES, EES was associated with a favourable vascular response at nine months after stent implantation.
authors.affiliation: Department of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Kubo
authors.forename: Takashi
authors.initials: T
authors.lastname: Akasaka
authors.forename: Ken
authors.initials: K
authors.lastname: Kozuma
authors.forename: Kazuo
authors.initials: K
authors.lastname: Kimura
authors.forename: Masaki
authors.initials: M
authors.lastname: Kawamura
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Sumiyoshi
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Ino
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Morino
authors.forename: Kengo
authors.initials: K
authors.lastname: Tanabe
authors.forename: Kazushige
authors.initials: K
authors.lastname: Kadota
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kimura
mesh_terms: D000368:Aged; D000789:Angina, Unstable / Q000209:etiology / Q000628:therapy; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology / Q000628:therapy; D058426:Neointima / Q000473:pathology*; D062645:Percutaneous Coronary Intervention; D020123:Sirolimus / Q000627:therapeutic use*; D041623:Tomography, Optical Coherence
chemical_list: D000970:Antineoplastic Agents; D000068338:Everolimus; D020123:Sirolimus